ESC 365 - PCSK9 inhibitors post Fourier: who should be treated and when?

ESC Premium Access

PCSK9 inhibitors post Fourier: who should be treated and when?

Session: Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Topic: Lipids (Epidemiology and Prevention)

Speaker: Professor S. Nissen (Cleveland, US)

Sponsored by Cleveland Clinic

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)

14 presentations

0 follower

3 more presentations in this session

siRNA therapy: the dawn of a new agent in cholesterol lowering?

Speaker: Doctor L. Cho (Cleveland, US)

Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

Speaker: Professor E. Stroes (Amsterdam, NL)

Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.

Speaker: Professor S. Nicholls (Melbourne, AU)

Access the full session

Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Speakers: Professor S. Nissen, Doctor L. Cho, Professor E. Stroes, Professor S. Nicholls

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources